Search

Your search keyword '"Nreu, Besmir"' showing total 45 results
Start Over Author "Nreu, Besmir"
45 results on '"Nreu, Besmir"'

1. A transparent machine learning algorithm uncovers HbA1c patterns associated with therapeutic inertia in patients with type 2 diabetes and failure of metformin monotherapy

Author

Musacchio, Nicoletta, Zilich, Rita, Masi, Davide, Baccetti, Fabio, Nreu, Besmir, Bruno Giorda, Carlo, Guaita, Giacomo, Morviducci, Lelio, Muselli, Marco, Ozzello, Alessandro, Pisani, Federico, Ponzani, Paola, Rossi, Antonio, Santin, Pierluigi, Verda, Damiano, Di Cianni, Graziano, and Candido, Riccardo

Published
2024
Full Text
View/download PDF

6. Overcoming Therapeutic Inertia in Type 2 Diabetes: Exploring Machine Learning-Based Scenario Simulation for Improving Short-Term Glycemic Control

Author

Nicoletta, Musacchio, primary, Zilich, Rita, additional, Masi, Davide, additional, Baccetti, Fabio, additional, Nreu, Besmir, additional, Giorda, Carlo Bruno, additional, Guaita, Giacomo, additional, Morviducci, Lelio, additional, Muselli, Marco, additional, Ozzello, Alessandro, additional, Pisani, Federico, additional, Ponzani, Paola, additional, Rossi, Antonio, additional, Santin, Pierluigi, additional, Verda, Damiano, additional, Cianni, Graziano Di, additional, and Candido, Riccardo, additional

Published
2024
Full Text
View/download PDF

23. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials

Author

Mannucci, Edoardo, primary, Nreu, Besmir, additional, Montereggi, Chiara, additional, Ragghianti, Benedetta, additional, Gallo, Marco, additional, Giaccari, Andrea, additional, Monami, Matteo, additional, Mannucci, Edoardo, additional, Candido, Riccardo, additional, Pintaudi, Basilio, additional, Targher, Giovanni, additional, Monache, Lina D., additional, Masini, Maria L., additional, Mazzone, Fulvia, additional, Medea, Gerardo, additional, Trento, Marina, additional, and Turchetti, Giuseppe, additional

Published
2021
Full Text
View/download PDF

36. Glucagon‐like peptide‐1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta‐analysis and subgroup analysis of randomized controlled trials.

Author

Mannucci, Edoardo, Dicembrini, Ilaria, Nreu, Besmir, and Monami, Matteo

Subjects
GLUCAGON-like peptide-1 receptor, DRUG-eluting stents, CARDIOVASCULAR diseases, RANDOMIZED controlled trials, GLUCAGON-like peptide-1 agonists, META-analysis, BODY mass index
Abstract

Aim: To conduct a meta‐analysis of cardiovascular outcome trials on the effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) on major adverse cardiovascular events (MACE). Methods: A search of MEDLINE, EMBASE, Cochrane database and clinicaltrials.gov was performed to identify controlled trials (up to 15 June 2019) of GLP‐1RAs with a cardiovascular endpoint. The principal endpoint of the present meta‐analysis was MACE; secondary endpoints included myocardial infarction, stroke, cardiovascular and all‐cause mortality, and hospitalization for heart failure. Mantel–Haenszel odds ratios (MH‐ORs) with 95% confidence intervals (CIs) were calculated for all outcomes. Results: In the seven trials included, all placebo‐controlled, GLP‐1RA treatment was associated with a reduction in MACE (MH‐OR 0.87 [95% CI 0.81, 0.93]). Cardiovascular and all‐cause mortality, myocardial infarction and stroke were also reduced (MH‐OR 0.88 [95% CI 0.80, 0.96], MH‐OR 0.90 [95% CI 0.82, 0.98], MH‐OR 0.91 [95% CI 0.84, 0.98] and MH‐OR 0.86 [95% CI 0.77, 0.97], respectively). Results for hospitalization for heart failure were not statistically significant (MH‐OR 0.93 [95% CI 0.83, 1.04]). The meta‐analyses of patient subgroups showed a significant reduction in MACE with GLP‐1RAs, irrespective of gender, advanced age and obesity. Conclusions: GLP‐1RAs are associated with a reduction in cardiovascular morbidity and mortality in high‐risk patients with diabetes. This effect does not appear to be moderated by gender or body mass index. The possibility of different effects of GLP‐1RAs between patients in primary and secondary prevention merits further investigation. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

44. Age, left atrial dimension and arterial stiffness after external cardioversion of atrial fibrillation. A vascular component in arrhythmia maintenance? Results from a preliminary study

Author

Fumagalli, Stefano, primary, Gabbai, Debbie, additional, Nreu, Besmir, additional, Roberts, Anna T., additional, Boni, Serena, additional, Ceccofiglio, Alice, additional, Fracchia, Stefania, additional, Baldasseroni, Samuele, additional, Tarantini, Francesca, additional, and Marchionni, Niccolò, additional

Published
2013
Full Text
View/download PDF

45. Rate and Predictors of Hesitancy toward SARS-CoV-2 Vaccine among Type 2 Diabetic Patients: Results from an Italian Survey

Author

Edoardo Mannucci, Davide Gori, Marco Montalti, Zeno Di Valerio, Besmir Nreu, Federica Guaraldi, Matteo Monami, Guaraldi, Federica, Montalti, Marco, Di Valerio, Zeno, Mannucci, Edoardo, Nreu, Besmir, Monami, Matteo, and Gori, Davide

Subjects
0301 basic medicine, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, Type 2 diabetes, Article, 03 medical and health sciences, 0302 clinical medicine, SARS-CoV-2 vaccine, Drug Discovery, Pandemic, medicine, Pharmacology (medical), 030212 general & internal medicine, Adverse effect, Pharmacology, type 2 diabete, High prevalence, business.industry, Type 2 Diabetes Mellitus, COVID-19, medicine.disease, Vaccination, 030104 developmental biology, Infectious Diseases, vaccine hesitancy, Medicine, type 2 diabetes, business, Demography
Abstract

Vaccine hesitancy (VH) has been identified as one of the major health concerns of our time by the World Health Organization. It may prove especially detrimental in the light of the ongoing SARS-CoV-2 pandemic, as vaccination campaigns still represent the primary strategy against the detrimental consequences of the pandemic. Among patients suffering from type 2 diabetes mellitus (DB), who are particularly vulnerable to COVID-19, VH might represent an even more serious threat. Therefore, our study focuses on identifying potential determinants of VH among patients with type 2 diabetes. Study participants (n = 1176) filled in a two-section online self-administered questionnaire, answering questions regarding demographic and anamnestic data, as well as their intention to accept any vaccination against COVID-19. Some possible reasons underlying VH were investigated as well. An overall hesitancy rate of 14.2% was registered. Data showed how older age, male gender, higher education level, and having been vaccinated for seasonal influenza in 2020–2021 were associated with a significantly higher propensity to receive the COVID-19 vaccine. On the contrary, having experienced adverse effects following past vaccinations was a negative predictor. In addition to confirming an array of predictors of VH, we found a worryingly high prevalence of VH among diabetics, who have been shown to be particularly exposed to severe COVID-19 and death. These findings may be useful in planning targeted action toward acceptance improvement and enhancing the efficacy of vaccination campaigns.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results